Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $123.9 million.

  • Crinetics Pharmaceuticals' Total Liabilities rose 1864.86% to $123.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.9 million, marking a year-over-year increase of 1864.86%. This contributed to the annual value of $109.8 million for FY2024, which is 1406.8% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Total Liabilities is $123.9 million, which was up 1864.86% from $118.0 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Total Liabilities peaked at $123.9 million during Q3 2025, and registered a low of $14.1 million during Q1 2021.
  • In the last 5 years, Crinetics Pharmaceuticals' Total Liabilities had a median value of $39.1 million in 2023 and averaged $64.9 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Total Liabilities plummeted by 891.44% in 2021, and later skyrocketed by 20648.18% in 2024.
  • Crinetics Pharmaceuticals' Total Liabilities (Quarter) stood at $19.1 million in 2021, then surged by 87.97% to $35.8 million in 2022, then skyrocketed by 168.49% to $96.2 million in 2023, then increased by 14.07% to $109.8 million in 2024, then grew by 12.82% to $123.9 million in 2025.
  • Its Total Liabilities was $123.9 million in Q3 2025, compared to $118.0 million in Q2 2025 and $107.3 million in Q1 2025.